Erectile dysfunction in diabetes mellitus

Cummings, Michael H.

doi:10.1002/9781118387658.ch67

Cited by 1 publication

(2 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The pathogenesis of diabetic ED (DED) is very complex and involves neurogenic, endothelial and smooth muscle dysfunction. From a clinical standpoint, vascular endothelial dysfunction, including vasoconstriction, and prothrombotic and proinflammatory status, plays a major role in the early development of ED in patients with diabetes 114 . The most widely used pharmacological agents for treating ED are phosphodiesterase 5 inhibitors; however, their use in diabetic populations is less effective and often associated with side effects 115 .…”

Section: Adipose‐derived Mesenchymal Stem Cell Action In Relieving Lo...mentioning

confidence: 99%

“…From a clinical standpoint, vascular endothelial dysfunction, including vasoconstriction, and prothrombotic and proinflammatory status, plays a major role in the early development of ED in patients with diabetes. 114 The most widely used pharmacological agents for treating ED are phosphodiesterase 5 inhibitors; however, their use in diabetic populations is less effective and often associated with side effects. 115 In recent years, a variety of preclinical and clinical studies have determined the safety and efficacy of stem cell-based therapies in the treatment of ED.…”

Section: Diabetic Erectile Dysfunctionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy of adipose‐derived mesenchymal stem cell therapy in the treatment of chronic micro‐ and macrovascular complications of diabetes

Mikłosz,

Chabowski

2023

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

Diabetes mellitus is a highly prevalent disease characterized by hyperglycaemia that damages the vascular system, leading to micro‐ (retinopathy, neuropathy, nephropathy) and macrovascular diseases (cardiovascular disease). There are also secondary complications of diabetes (cardiomyopathy, erectile dysfunction or diabetic foot ulcers). Stem cell‐based therapies have become a promising tool targeting diabetes symptoms and its chronic complications. Among all stem cells, adipose‐derived mesenchymal stem cells (ADMSCs) are of great importance because of their abundance, non‐invasive isolation and no ethical limitations. Characteristics that make ADMSCs good candidates for cell‐based therapy are their wide immunomodulatory properties and paracrine activities through the secretion of an array of growth factors, chemokines, cytokines, angiogenic factors and anti‐apoptotic molecules. Besides, after transplantation, ADMSCs show great ex vivo expansion capacity and differentiation to other cell types, including insulin‐producing cells, cardiomyocytes, chondrocytes, hepatocyte‐like cells, neurons, endothelial cells, photoreceptor‐like cells, or astrocytes. Preclinical studies have shown that ADMSC‐based therapy effectively improved visual acuity, ameliorated polyneuropathy and foot ulceration, arrested the development and progression of diabetic kidney disease, or alleviated the diabetes‐induced cardiomyocyte hypertrophy. However, despite the positive results obtained in animal models, there are still several challenges that need to be overcome before the results of preclinical studies can be translated into clinical applications. To date, there are several clinical trials or ongoing trials using ADMSCs in the treatment of diabetic complications, most of them in the treatment of diabetic foot ulcers. This narrative review summarizes the most recent outcomes on the usage of ADMSCs in the treatment of long‐term complications of diabetes in both animal models and clinical trials.

show abstract

Section: Adipose‐derived Mesenchymal Stem Cell Action In Relieving Lo...mentioning

confidence: 99%

Section: Diabetic Erectile Dysfunctionmentioning

confidence: 99%